# US 2022/0064164 A1 · 1,2,4-oxadiazole derivatives as liver x receptor agonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0064164 A1
- Document ID: US20220064164A1
- Status: Published application
- Kind: A1
- Application number: 17/101,510
- Filed: 2020-11-23
- Published: 2022-03-03
- Earliest claimed: 2019-11-25
- Assignees: Novartis AG
- Applicants: Novartis AG
- Inventors: Kelly D. BOSS; Yi FAN; Alec Nathanson FLYER; Declan HARDY; Zhihong HUANG; Kathryn Taylor LINKENS; Jon Christopher LOREN; Fupeng MA; Valentina MOLTENI; Duncan SHAW; Jeffrey SMITH; Catherine Fooks SOLOVAY
- Web page: https://patentgrep.com/patent/US20220064164A1

## CPC

- C07D 471/10: Spiro-condensed systems
- A61P 27/00: Drugs for disorders of the senses
- A61P 27/04: Artificial tears; Irrigation solutions
- C07D 413/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 413/14: containing three or more hetero rings
- C07D 491/107: with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Provided herein are compounds and pharmaceutical compositions useful for treating meibomian gland dysfunction (MGD), comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a compound of Formula (I′), or pharmaceutical composition described herein.

## Claims

### Claim 1

A compound according to Formula (I):
or a pharmaceutically acceptable salt, solvate, co-crystal, polymorph, or stereoisomer thereof, wherein:
R1 is
C1-C6alkyl,
phenyl, or
5-6 membered heteroaryl having 1 to 3 heteroatoms independently selected from the heteroatoms N, O and S as ring members,
wherein the phenyl and heteroaryl are optionally substituted with one R10, and the C1-C6alkyl is substituted with one or two —CF3;
R2 is —CF3 or Cl;
R3a is
H, or
C1-C6alkyl optionally substituted with one, two, or three substituents independently selected from the group consisting of —OH and —N(R12)2;
R3b is
H, or
C1-C6alkyl optionally substituted with one, two, or three substituents independently selected from the group consisting of —OH and —N(R12)2;
or R3a and R3b together with the carbon atom they are attached to may combine to form a C3-C8cycloalkyl, wherein the cycloalkyl is optionally substituted with one R5;
or R3a and R3b together with the carbon atom they are attached to may combine to form a 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR12, O or S, wherein the heterocycloalkyl is optionally substituted with one R5;
R4 is C1-C6alky 1 substituted with one or two groups independently selected from:
R6,
4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR12, O or S,
5-6 membered heteroaryl having 1 to 3 heteroatoms independently selected from the heteroatoms N, O and S as ring members, and
C3-C8cycloalkyl,
wherein the heterocycloalkyl is optionally substituted with one or two substituents independently selected from —OH and C1-C3alkyl;
each R5 is independently selected from:
—C(═O)R8,
C1-C3alkyl,
C3-C8cycloalkyl, and
4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR12, O or S,
wherein the C1-C3alkyl is optionally substituted with one R9, and the heterocycloalkyl is optionally substituted with one C1-C3alkyl or —C(═O)R8;
each R6 is independently selected from —OH and C1-C3alkyl;
R7 is
C1-C6alkyl,
—N(R12)2,
C3-C8cycloalkyl, or
4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR12, O or S,
wherein the C1-C6alkyl is optionally substituted with one or more R11, and the C3-C8cycloalkyl is optionally substituted with one or more —OH;
R8 is
C1-C6alkyl,
5-6 membered heteroaryl having 1 to 3 heteroatoms independently selected from the heteroatoms N, O and S as ring members, or
4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR12, O or S,
wherein the heterocycloalkyl is optionally substituted with one C1-C6alkyl, and the C1-C6alkyl is optionally substituted with one or more substituents selected from the group consisting of —C(═O)OH, N(R12)2, and C3-C8cycloalkyl;
R9 is
phenyl,
C3-C8cycloalkyl,
4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR12, O or S, or
5-6 membered heteroaryl having 1 to 3 heteroatoms independently selected from the heteroatoms N, O and S as ring members,
wherein the heteroaryl is optionally substituted with —OH, the heterocycloalkyl is optionally substituted with C1-C6alkyl, and the phenyl is optionally substituted with one or two —OH;
R10 is C1-C6alkyl or C1-C6haloalkyl;
each R11 is independently selected from
halogen,
C1-C6haloalkyl,
C1-C6alkoxy,
—N(R13)2,
—OH, and
4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR12, O or S;
each R12 is independently selected from H and C1-C6alkyl, and
each R13 is independently selected from
H, and
C1-C6alkyl,
wherein the alkyl is optionally substituted with —OH or C1-C6alkoxy.

### Claim at position 2

-4. (canceled)

### Claim 5 (depends on 1)

The compound according to claim 1, wherein the compound is a compound of Formula (Ia)
or a pharmaceutically acceptable salt, solvate, co-crystal, polymorph or stereoisomer thereof, wherein:
X is NR5, CH2, or O;
n is 0 or 1, and
m is 0 or 1.

### Claim at position 4

-15. (canceled)

### Claim 16 (depends on 1)

The compound according to claim 1, wherein the compound is a compound of Formula (Ie)
or a pharmaceutically acceptable salt, solvate, co-crystal, polymorph or stereoisomer thereof.

### Claim at position 6

-19. (canceled)

### Claim 20 (depends on 1)

The compound according to claim 1, wherein the compound is selected from the group consisting of:
5,5-dimethyl-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3-((3-(4-(3,3,3-trifluoro-2-methyl-2-(trifluoromethyl)propoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)imidazolidine-2,4-dione;
3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-5-methyl-1-(2-morpholinoethyl)-5-propylimidazolidine-2,4-dione;
3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-1-(2-morpholinoethyl)-1,3-diazaspiro[4.5]decane-2,4-dione;
3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-5,5-dimethyl-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)imidazolidine-2,4-dione;
2-(4-(5-((4,4-dimethyl-2,5-dioxo-3-(2-(tetrahydro-2H-pyran-4-yl)ethyl)imidazolidin-1-yl)methyl)-1,2,4-oxadiazol-3-yl)-2-(trifluoromethyl)phenoxy)-N-isopropyl-N-methylbenzenesulfonamide;
1-(2-(4-hydroxytetrahydro-2H-pyran-4-yl)ethyl)-3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-5,5-dimethylimidazolidine-2,4-dione;
3-((3-(4-(2-(tert-butyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-8-cyclobutyl-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione;
8-cyclobutyl-3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-1-(2-morpholinoethyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione;
3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-1-(2-morpholinoethyl)-1,3,8-triazaspiro[4.5]decane-2,4-di one;
3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-8-methyl-1-(2-morpholinoethyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione;
2-(4-(5-((8-cyclobutyl-1-(2-morpholinoethyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-3-yl)methyl)-1,2,4-oxadiazol-3-yl)-2-(trifluoromethyl)phenoxy)-N-isopropyl-N-methylbenzenesulfonamide;
8-cyclobutyl-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3-((3-(3-(trifluoromethyl)-4-(2-(trifluoromethyl)phenoxy)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione;
8-cyclobutyl-1-(2-morpholinoethyl)-3-((3-(3-(trifluoromethyl)-4-(2-(trifluoromethyl)phenoxy)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione;
8-cyclobutyl-1-(2-morpholinoethyl)-3-((3-(4-(3,3,3-trifluoro-2-methyl-2-(trifluoromethyl)propoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione;
8-cyclobutyl-3-((3-(4-(2-(methylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-1-(2-morpholinoethyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione;
3-((3-(4-(2-(tert-butyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-8-cyclobutyl-1-(2-morpholinoethyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione;
8-cyclobutyl-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3-((3-(4-(2-((2,2,2-trifluoroethyl)sulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione;
8-cyclobutyl-3-((3-(4-(2-(methylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione;
8-cyclobutyl-1-(2-morpholinoethyl)-3-((3-(4-(2-(((tetrahydrofuran-2-yl)methyl)sulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione;
8-cyclobutyl-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3-((3-(4-(2-(((tetrahydrofuran-2-yl)methyl)sulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione;
8-(4-hydroxybenzyl)-3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-1-(2-morpholinoethyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione;
8-(3,5-dihydroxybenzyl)-3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-1-(2-morpholinoethyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione;
3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-8-(1-methylpiperidin-4-yl)-1-(2-morpholinoethyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione;
3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-8-(1-methylpyrrolidin-3-yl)-1-(2-morpholinoethyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione;
8-ethyl-3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-1-(2-morpholinoethyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione;
3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-1-(2-morpholinoethyl)-8-(pyridazin-3-ylmethyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione;
3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-1-(2-morpholinoethyl)-8-((tetrahydro-2H-pyran-4-yl)methyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione;
8-(cyclopropylmethyl)-3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-1-(2-morpholinoethyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione;
8-(2-cyclopropylacetyl)-3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-1-(2-morpholinoethyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione;
3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-1-(2-morpholinoethyl)-8-(pyrimidine-5-carbonyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione;
1-(2-morpholinoethyl)-8-(pyrimidine-5-carbonyl)-3-((3-(4-(3,3,3-trifluoro-2-methyl-2-(trifluoromethyl)propoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione;
8-(pyrimidine-5-carbonyl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3-((3-(4-(3,3,3-trifluoro-2-methyl-2-(trifluoromethyl)propoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-1,3,8-triazaspiro[4.5]decane-2,4-di one;
8-(3-(dimethylamino)propanoyl)-3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-1-(2-morpholinoethyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione;
3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-8-(1-methylpiperidine-4-carbonyl)-1-(2-morpholinoethyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione;
3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-1-(2-morpholinoethyl)-8-(pyrimidine-4-carbonyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione;
8-butyryl-3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-1-(2-morpholinoethyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione;
3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-8-(pyrazine-2-carbonyl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione;
3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-8-(pyrimidine-5-carbonyl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione;
5,5-dimethyl-1-(2-morpholinoethyl)-3-((3-(4-(2-(((tetrahydrofuran-3-yl)methyl)sulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)imidazolidine-2,4-dione;
3-((3-(4-(2-((3-hydroxycyclobutyl)sulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-5,5-dimethyl-1-(2-morpholinoethyl)imidazolidine-2,4-di one;
5,5-dimethyl-1-(2-morpholinoethyl)-3-((3-(4-(2-(((tetrahydro-2H-pyran-3-yl)methyl)sulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)imidazolidine-2,4-dione;
5,5-dimethyl-1-(2-morpholinoethyl)-3-((3-(3-(trifluoromethyl)-4-(2-(trifluoromethyl)phenoxy)phenyl)-1,2,4-oxadiazol-5-yl)methyl)imidazolidine-2,4-dione;
5,5-dimethyl-1-(2-morpholinoethyl)-3-((3-(4-(3,3,3-trifluoro-2-methyl-2-(trifluoromethyl)propoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)imidazolidine-2,4-dione;
5,5-dimethyl-1-(2-morpholinoethyl)-3-((3-(4-(2-((2-(pyrrolidin-1-yl)propyl)sulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)imidazolidine-2,4-dione;
3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-1-(2-morpholinoethyl)imidazolidine-2,4-dione;
3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-1-(2-morpholinoethyl)-1,3-diazaspiro[4.5]decane-2,4-dione;
7-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-5-(2-morpholinoethyl)-5,7-diazaspiro[3.4]octane-6,8-dione;
5-(hydroxymethyl)-3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-5-methyl-1-(2-morpholinoethyl)imidazolidine-2,4-dione;
8-cyclobutyl-1-(2-morpholinoethyl)-3-((3-(4-(2-((2,2,2-trifluoroethyl)sulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione;
3-((3-(3-chloro-4-(2-(isobutylsulfonyl)phenoxy)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-5,5-dimethyl-1-(2-morpholinoethyl)imidazolidine-2,4-dione;
3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-5,5-dimethyl-1-(3-(pyrrolidin-1-yl)propyl)imidazolidine-2,4-dione;
3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-5,5-dimethyl-1-(pyridin-2-ylmethyl)imidazolidine-2,4-di one;
3-((3-(4-(2-((2-hydroxypropyl)sulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-5,5-dimethyl-1-(2-morpholinoethyl)imidazolidine-2,4-di one;
5,5-dimethyl-1-(2-morpholinoethyl)-3-((3-(4-(2-(((tetrahydro-2H-pyran-2-yl)methyl)sulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)imidazolidine-2,4-dione;
1-(cyclopropylmethyl)-3-((3-(4-(2-((2-methoxyethyl)sulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-5,5-dimethylimidazolidine-2,4-dione;
5,5-dimethyl-3-((3-(4-(2-(methylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-1-(2-morpholinoethyl)imidazolidine-2,4-dione;
1-(2-morpholinoethyl)-3-((3-(4-(2-(((tetrahydrofuran-2-yl)methyl)sulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-8-oxa-1,3-diazaspiro[4.5]decane-2,4-dione;
3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-5,5-dimethyl-1-(2-morpholinoethyl)imidazolidine-2,4-dione;
3-((3-(4-(2-((2-methoxyethyl)sulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-5,5-dimethyl-1-(2-morpholinoethyl)imidazolidine-2,4-di one;
5,5-dimethyl-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3-((3-(4-(2-((tetrahydrofuran-3-yl)sulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)imidazolidine-2,4-dione;
5-((dimethylamino)methyl)-3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-5-methyl-1-(2-morpholinoethyl)imidazolidine-2,4-dione;
3-((3-(4-(2-((2-(bis(2-methoxyethyl)amino)ethyl)sulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-5,5-dimethyl-1-(2-morpholinoethyl)imidazolidine-2,4-dione;
3-((3-(4-(2-((2-(bis(2-hydroxyethyl)amino)ethyl)sulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-5,5-dimethyl-1-(2-morpholinoethyl)imidazolidine-2,4-dione;
5,5-dimethyl-1-(2-morpholinoethyl)-3-((3-(4-(2-(((tetrahydrofuran-2-yl)methyl)sulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)imidazolidine-2,4-dione;
(R or S) 5,5-dimethyl-1-(2-morpholinoethyl)-3-((3-(4-(2-(((tetrahydrofuran-2-yl)methyl)sulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)imidazolidine-2,4-dione, and
(R or S) 5,5-dimethyl-1-(2-morpholinoethyl)-3-((3-(4-(2-(((tetrahydrofuran-2-yl)methyl)sulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)imidazolidine-2,4-dione.

### Claim 21 (depends on 20)

The compound of claim 20, wherein the compound is 3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-5,5-dimethyl-1-(2-morpholinoethyl)imidazolidine-2,4-dione.

### Claim 22 (depends on 20)

The compound of claim 20, wherein the compound is 8-cyclobutyl-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-3-((3-(4-(3,3,3-trifluoro-2-methyl-2-(trifluoromethyl)propoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione or a pharmaceutically acceptable salt thereof.

### Claim 23 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt, solvate, co-crystal, polymorph, or stereoisomer thereof, and one or more pharmaceutically acceptable carriers.

### Claim 24 (depends on 1)

A method for the treatment of meibomian gland dysfunction comprising administration of a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt, solvate, co-crystal, polymorph or stereoisomer thereof, to a patient in need of treatment thereof.

### Claim at position 12

-27. (canceled)

### Claim 28

A crystalline form of 3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-5,5-dimethyl-1-(2-morpholinoethyl)imidazolidine-2,4-dione characterized by an X-ray powder diffraction pattern comprising one or more peaks at 2-Theta angles selected from 7.2±0.2, 7.8±0.2, 8.2±0.2, 10.7±0.2, 11.6±0.2, 12.5±0.2, 13.8±0.2, 14.5±0.2, 15.0±0.2, 15.8±0.2, 17.7±0.2, 18.9±0.2, 20.7±0.2, 21.3±0.2, 21.8±0.2, 22.1±0.2, and 23.1±0.2.

### Claim 29

A compound according to Formula (T):
or a pharmaceutically acceptable salt, solvate, co-crystal, polymorph, or stereoisomer thereof, wherein:
R1 is
C1-C6alkyl,
phenyl or
5-6 membered heteroaryl having 1 to 3 heteroatoms independently selected from the heteroatoms N, O and S as ring members,
wherein the phenyl and heteroaryl are optionally substituted with one R10′, and the C1-C6alkyl is optionally substituted with one or two —CF3;
R2 is C1-C6haloalkyl or halo;
R3a is
hydrogen or
C1-C6alkyl optionally substituted with one, two, or three substituents independently selected from the group consisting of —OH and —N(R12′)2;
R3b is
hydrogen or
C1-C6alkyl optionally substituted with one, two, or three substituents independently selected from the group consisting of —OH and —N(R12′)2;
or R3a and R3b together with the carbon atom they are attached to may combine to form a C3-C8cycloalkyl, wherein said cycloalkyl is optionally substituted with one R5;
or R3a and R3b together with the carbon atom they are attached to may combine to form a 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR12′, O and S, wherein said heterocycloalkyl is optionally substituted with one R5;
R4 is
hydrogen, or
C1-C6alkyl optionally substituted with one or two groups independently selected from:
R6,
4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR12′, O and S,
5-6 membered heteroaryl having 1 to 3 heteroatoms independently selected from the heteroatoms N, O and S as ring members, and
C3-C8cycloalkyl,
wherein the heterocycloalkyl is optionally substituted with one or two substituents independently selected from —OH and C1-C3alkyl;
each R5 is independently selected from
—C(═O)R8,
C1-C3alkyl,
C3-C8cycloalkyl, and
4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR12′, O and S,
wherein the C1-C3alkyl is optionally substituted with one R9, and the heterocycloalkyl is optionally substituted with one C1-C3alkyl or —C(═O)R8;
each R6 is independently selected from —OH and C1-C3alkyl;
R7 is
C1-C6alkyl,
—N(R12′)2,
C3-C8cycloalkyl, or
4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR12′, O and S,
wherein the C1-C6alkyl is optionally substituted with one or more R11, and the C3-C8cycloalkyl is optionally substituted with one or more —OH;
R8 is
C1-C6alkyl,
C1-C6alkyl-COOH,
5-6 membered heteroaryl having 1 to 3 heteroatoms independently selected from the heteroatoms N, O and S as ring members, or
4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR12′, O and S,
wherein the heterocycloalkyl is optionally substituted with one C1-C6alkyl, and the C1-C6alkyl is optionally substituted with one or more substituents selected from the group consisting of —C(═O)OH, N(R12)2, and C3-C8cycloalkyl;
R9 is
phenyl,
C3-C8cycloalkyl,
4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR12′, O and S, or
5-6 membered heteroaryl having 1 to 3 heteroatoms independently selected from the heteroatoms N, O and S as ring members,
wherein the heteroaryl is optionally substituted with —OH, the heterocycloalkyl is optionally substituted with C1-C6alkyl, and the phenyl is optionally substituted with one or two —OH;
R10′ is C1-C6alkyl, C1-C6haloalkyl, or S—CF3;
each R11 is independently selected from
halogen,
C1-C6haloalkyl,
C1-C6alkoxy,
—N(R13)2,
—OH, and
4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR12′, O and S;
each R12 is independently selected from
hydrogen,
C1-C6alkyl, and
—C(═O)R8; and
each R13 is independently selected from
hydrogen, and
C1-C6alkyl,
wherein the alkyl is optionally substituted with —OH or C1-C6alkoxy.

### Claim at position 15

-48. (canceled)

### Claim 49 (depends on 29)

The compound according to claim 29, wherein the compound is selected from the group consisting of:
3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-5,5-dimethylimidazolidine-2,4-dione,
5,5-dimethyl-1-(2-morpholinoethyl)-3-((3-(3-(trifluoromethyl)-4-((4-(trifluoromethyl)pyridin-3-yl)oxy)phenyl)-1,2,4-oxadiazol-5-yl)methyl)imidazolidine-2,4-dione,
5,5-dimethyl-1-(2-morpholinoethyl)-3-((3-(3-(trifluoromethyl)-4-(3,3,3-trifluoropropoxy)phenyl)-1,2,4-oxadiazol-5-yl)methyl)imidazolidine-2,4-dione,
6-(3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-1-(2-morpholinoethyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-6-oxohexanoic acid,
4-(3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-1-(2-morpholinoethyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-4-oxobutanoic acid,
6-(1-(2-morpholinoethyl)-2,4-di oxo-3-((3-(3-(trifluoromethyl)-4-(2-(trifluoromethyl)phenoxy)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-1,3,8-triazaspiro[4.5]decan-8-yl)-6-oxohexanoic acid,
5,5-dimethyl-3-((3-(3-(trifluoromethyl)-4-(2-((trifluoromethyl)thio)phenoxy)phenyl)-1,2,4-oxadiazol-5-yl)methyl)imidazolidine-2,4-dione,
5,5-dimethyl-3-((3-(3-(trifluoromethyl)-4-(2-(trifluoromethyl)phenoxy)phenyl)-1,2,4-oxadiazol-5-yl)methyl)imidazolidine-2,4-dione, and
1,5,5-trimethyl-3-((3-(3-(trifluoromethyl)-4-(2-(trifluoromethyl)phenoxy)phenyl)-1,2,4-oxadiazol-5-yl)methyl)imidazolidine-2,4-dione,
or a pharmaceutically acceptable salt thereof.

### Claim 50 (depends on 29)

A pharmaceutical composition comprising a compound according to claim 29, or a pharmaceutically acceptable salt, solvate, co-crystal, polymorph, or stereoisomer thereof, and one or more pharmaceutically acceptable carriers.

### Claim 51 (depends on 29)

A method for the treatment of meibomian gland dysfunction comprising administration of a therapeutically effective amount of a compound according to claim 29, or a pharmaceutically acceptable salt, solvate, co-crystal, polymorph or stereoisomer thereof, to a patient in need of treatment thereof.

### Claim at position 19

-54. (canceled)

### Claim 55 (depends on 1)

A method for the treatment of evaporative dry eye disease comprising administration of a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt, solvate, co-crystal, polymorph or stereoisomer thereof, to a patient in need of treatment thereof.

### Claim at position 21

-58. (canceled)

### Claim 59 (depends on 1)

A method for the treatment of an ocular disease or disorder comprising administration of a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt, solvate, co-crystal, polymorph or stereoisomer thereof, to a patient in need of treatment thereof.

### Claim at position 23

-65. (canceled)

### Claim 66 (depends on 49)

A method for the treatment of meibomian gland dysfunction comprising administration of a therapeutically effective amount of a compound according to claim 49, or a pharmaceutically acceptable salt, solvate, co-crystal, polymorph or stereoisomer thereof, to a patient in need of treatment thereof.

### Claim 67 (depends on 49)

A method for the treatment of evaporative dry eye disease comprising administration of a therapeutically effective amount of a compound according to claim 49, or a pharmaceutically acceptable salt, solvate, co-crystal, polymorph or stereoisomer thereof, to a patient in need of treatment thereof.

### Claim 68 (depends on 49)

A method for the treatment of an ocular disease or disorder comprising administration of a therapeutically effective amount of a compound according to claim 49, or a pharmaceutically acceptable salt, solvate, co-crystal, polymorph or stereoisomer thereof, to a patient in need of treatment thereof.

### Claim 69 (depends on 20)

A method for the treatment of meibomian gland dysfunction comprising administration of a therapeutically effective amount of a compound according to claim 20, or a pharmaceutically acceptable salt, solvate, co-crystal, polymorph or stereoisomer thereof, to a patient in need of treatment thereof.

### Claim 70 (depends on 20)

A method for the treatment of evaporative dry eye disease comprising administration of a therapeutically effective amount of a compound according to claim 20, or a pharmaceutically acceptable salt, solvate, co-crystal, polymorph or stereoisomer thereof, to a patient in need of treatment thereof.

### Claim 71 (depends on 20)

A method for the treatment of an ocular disease or disorder comprising administration of a therapeutically effective amount of a compound according to claim 20, or a pharmaceutically acceptable salt, solvate, co-crystal, polymorph or stereoisomer thereof, to a patient in need of treatment thereof.
